About
FLIP: Fatty Liver Insights is an independent educational website focused on explaining the science, research, and clinical understanding of fatty liver disease in clear, practical language. The site is inspired by the original FLIP FP7 European research project, which studied how fatty liver disease progresses and how it can be better diagnosed, understood, and prevented through coordinated scientific research across Europe.
This website does not provide medical advice. It does not represent a clinic, a hospital, or a medical authority. Its purpose is to make complex liver research understandable to readers who want to learn how fatty liver disease develops, how it is measured, and how researchers and clinicians think about prevention and progression.
The content is written for people who want to understand the condition from a research and evidence perspective: patients trying to interpret test results, readers interested in metabolic health, students, health writers, and anyone who encounters terms such as NAFLD, NASH, MASLD, fibrosis staging, or liver biomarkers and wants clear explanations grounded in published science.
What was the original FLIP FP7 project?
The name “FLIP” comes from the European research project Fatty Liver: Inhibition of Progression, funded under the Seventh Framework Programme (FP7) of the European Commission. The project brought together universities, hospitals, and research institutes to study how fatty liver disease advances from simple fat accumulation in the liver to inflammation, fibrosis, cirrhosis, and liver cancer.
A central goal of the project was to build one of the largest European cohorts of patients with biopsy-confirmed fatty liver disease, supported by detailed clinical data and biological samples. This allowed researchers to study:
- How metabolic factors such as obesity and insulin resistance influence liver damage
- How inflammation and fibrosis develop over time
- Which biomarkers could improve diagnosis and prognosis
- How histological classification of the disease could be standardised
- Which epidemiological patterns could explain rising rates in adults and adolescents
The original project website served as a dissemination portal for this research. This current site continues in the same spirit by translating scientific knowledge into accessible explanations, without presenting itself as a medical institution.
Why fatty liver disease is a major topic in 2026
Fatty liver disease has become one of the most common chronic conditions worldwide. It is closely linked to metabolic dysfunction, insulin resistance, type 2 diabetes, obesity, and modern dietary patterns. In recent years, medical terminology has evolved from NAFLD and NASH to MASLD and MASH to better reflect the central role of metabolic health in the disease.
Researchers, clinicians, and public health agencies now view fatty liver disease as:
- A leading cause of chronic liver damage
- A growing reason for liver transplantation
- A risk factor for liver cancer
- A condition deeply connected to cardiovascular and metabolic disease
This growing relevance means more people encounter liver enzyme tests, imaging reports, fibrosis scores, and unfamiliar medical terms. The need for clear, research-based explanations has increased accordingly.
Who this site is for
This site is written for readers who want to understand the science behind fatty liver disease without needing a medical background. Typical readers include:
- People diagnosed with fatty liver who want to understand what test results mean
- Readers researching the link between metabolism and liver health
- Health writers and students looking for clear explanations of clinical terms
- People interested in how research studies measure and classify the disease
- Anyone trying to understand the difference between NAFLD, NASH, MASLD, and MASH
The articles focus on explaining how researchers and clinicians describe the disease, how it is measured, and what factors are known to influence progression.
What this site does not do
Clarity about limitations is important for trust. This website:
- Does not provide medical advice or treatment recommendations
- Does not diagnose conditions
- Does not replace consultation with qualified healthcare professionals
- Does not promote supplements, products, or therapies
When prevention strategies, dietary patterns, or lifestyle factors are discussed, they are presented in the context of what research studies have observed, not as prescriptions.
How the content is created
Articles are based on published research, clinical guidelines, and established medical understanding of fatty liver disease. The aim is to translate terminology used in journals and clinical reports into plain language while keeping the meaning accurate.
This involves explaining:
- What liver enzymes indicate and what they do not
- What fibrosis stages represent in practical terms
- How imaging, biopsy, and biomarkers are used in research and clinics
- How metabolic factors influence liver outcomes
- How researchers design studies and cohorts to understand progression
Technical terms are defined in context rather than simplified to the point of losing meaning.
Why research translation matters
Scientific papers are written for specialists. They assume familiarity with terminology, methods, and clinical practice. For readers outside medicine, this creates a gap between what research says and what people understand.
This site sits in that gap. It does not simplify by removing important detail. Instead, it explains what the detail means in everyday terms, so readers can follow the logic of how doctors and researchers interpret fatty liver disease.
Continuity with the original FLIP project
Although this website is independent from the original EU project, it follows the same underlying purpose: improving understanding of how fatty liver disease progresses and how it is studied. The focus remains on:
- Disease progression from fat accumulation to fibrosis and cancer
- Diagnostic and prognostic markers
- Standardised ways of classifying liver damage
- The role of metabolic and inflammatory processes
This continuity preserves the educational spirit of the original project while presenting current knowledge in an accessible form.
How to read the articles on this site
Articles are structured around common real-world questions, such as:
- What does a specific test result mean?
- What is the difference between stages of fibrosis?
- Why is insulin resistance relevant to liver health?
- How do researchers measure disease progression?
- What do new terms like MASLD and MASH mean?
Each article aims to answer one topic fully and clearly, without assuming prior knowledge.
A note on terminology changes
Medical terminology around fatty liver disease has evolved. Readers may encounter older terms (NAFLD, NASH) and newer ones (MASLD, MASH). This site explains both and clarifies how they relate to each other, because many research papers and clinical reports still use earlier terminology.
Why neutrality and clarity are priorities
Health information is often presented with strong opinions, trends, or commercial influence. This site takes a different approach. The goal is to present what research shows, how clinicians interpret it, and where uncertainties still exist.
This neutral approach allows readers to form their own understanding based on evidence rather than persuasion.
The long-term aim of this resource
Fatty liver disease is not a short-term topic. It is closely tied to long-term trends in metabolic health, diet, and lifestyle. As research continues to evolve, the need for clear explanations will remain.
This site aims to serve as a stable, understandable reference point for readers trying to navigate complex medical information about liver health.
By staying focused on evidence, clarity, and research translation, FLIP: Fatty Liver Insights continues the educational legacy associated with the original European project while remaining independent, transparent, and accessible.